A 47-year-old patient developed progressive upper limb weakness and hyperreflexia over 4 years. Lower limb examination had normal results. Nerve conduction, EMG, and brain and spine MRI had normal results. FDG-PET demonstrated severe bilateral hypometabolism in the primary motor cortex (figure, A and B). In the correct clinical context, this stripe of hypometabolism supports a diagnosis of primary lateral sclerosis (PLS) 1 -a rare motor neuron disease characterized by degeneration of upper motor neurons only. However, this pattern of hypometabolism can also occur in amyotrophic lateral sclerosis (ALS) 2 -therefore, FDG-PET cannot be used to differentiate between ALS and PLS.
Teaching NeuroImages: Hypometabolism of the primary motor cortex in primary lateral sclerosis
The stripe sign A 47-year-old patient developed progressive upper limb weakness and hyperreflexia over 4 years. Lower limb examination had normal results. Nerve conduction, EMG, and brain and spine MRI had normal results. FDG-PET demonstrated severe bilateral hypometabolism in the primary motor cortex ( figure, A and B) . In the correct clinical context, this stripe of hypometabolism supports a diagnosis of primary lateral sclerosis (PLS) 1 -a rare motor neuron disease characterized by degeneration of upper motor neurons only. However, this pattern of hypometabolism can also occur in amyotrophic lateral sclerosis (ALS) 2 -therefore, FDG-PET cannot be used to differentiate between ALS and PLS.
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